BioSpace News Archive

Policy

WHO denounces GSK-VIR, Regeneron COVID drugs following Lancet Criticism

The Lancet Commission published a lengthy criticism of the WHO’s COVID-19 pandemic response. In turn, the WHO offered a reply to a number of the complaints.

September 16, 2022
·
5 min read
·
Mark Terry
Research Roundup: Brain Inflammation in Monkeypox, Repurposing Drugs for Autism & More

Neuronal Inflammation was found in two U.S. monkeypox patients, researchers short-list four drugs for potential study in autism and a new test can predict immunotherapy outcomes.

September 16, 2022
·
4 min read
·
Katherine Davis
Policy

FDA Review: Abiomed, Mallinckrodt, Aro and More

The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.

September 16, 2022
·
3 min read
·
Mark Terry
Drug Development

FDA Action Alert: Regeneron, Spectrum and More

The FDA has two PDUFA dates on its calendar this week, with two extra days slotted for an advisory committee meeting to evaluate drug applications from three companies.

September 16, 2022
·
3 min read
·
Mark Terry
Business

Palisade Bio Axes Staff, Streamlines Operations to Keep Lead Asset on Track

Palisade Bio is laying off 20 percent of its workforce, the company announced Thursday. The cost-saving measures are expected to amount to over $1.5 million per annum.

September 16, 2022
·
2 min read
·
Paul Elias
Drug Development

Intellia’s Latest Data Indicate Full Potential of CRISPR

Intellia Therapeutics reported early, positive signs from its in vivo gene therapies for both transthyretin (ATTR) amyloidosis and hereditary angioedema Friday.

September 16, 2022
·
3 min read
·
Alex Keown
FDA

Merck Capitalizes on Keytruda’s Combination Potential

With 33 approvals from the FDA, Merck’s checkpoint inhibitor Keytruda has become a powerhouse oncology drug and is likely to continue to rack up more regulatory wins.

September 16, 2022
·
4 min read
·
Alex Keown
Drug Development

Mallinckrodt’s Terlivaz Becomes First FDA-Approved Drug for Hepatorenal Syndrome

The U.S. FDA approved Mallinckrodt’s Terlivaz in adults with hepatorenal syndrome and is the only FDA-approved drug for that indication.

September 16, 2022
·
3 min read
·
Mark Terry
Career Advice

What You Need to Know to Become a Biochemist

Becoming a chemist in the biopharma industry takes hard work, dedication and a willingness to continuously learn. Here’s what you need to know to become a biochemist.

September 16, 2022
·
5 min read
·
Franklin Carpenter
5 Lupus Patients in Remission Following CAR T Cell Therapy

Five patients with systemic lupus erythematosus (SLE) are in remission after receiving CAR T cell therapy, according to a recent study.

September 16, 2022
·
2 min read
·
Tristan Manalac